Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 287

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 287
---
 dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

| 4. | In March 2019, the Company participated in the Horizon 2020 Research                                                                          
 and Innovation Framework Programme from European Union through the EASME for its participation in research and development activities         
 of the Company. Pursuant to the participation in the Programme, the EASME will fund R&D expenses up to total approved budget of approximately 
 $2,680 (EURO 2,185 thousand), out of which $1,095 (EURO 983 thousand) was received in 2019 and $1,039 (EURO 874 thousand) was received        
 in 2021. As of December 31, 2023, the Company, recorded the amount received as a grant liability in other accounts payable in balance         
 sheets (refer to Note 4). The grant liability will be recorded as reduction in research and development expenses once the Company receives    
 approval of the project completion. Considering the grantor’s entitlement to demand a complete reimbursement of the entire grant,             
 pending the ultimate approval of the project completion, the Company has not yet recognized income from this grant.                           
 In April 2024, the Company received the approval                                                                                              
 (refer to Note 14).                                                                                                                           |

| 5. | In January 2024, the Company renewed its facility lease agreement until December 2024. The monthly rental obligations under non-cancellable leases are approximately $5.5 (including $3 for administrative expenses). |

As part of the agreement, the Company
has provided the landlord with a bank guarantee of approximately of $7 (NIS 27 thousand) which is valid until February 2025.

Future minimum lease payments under non-cancelable
operating leases as of December 31, 2023 are as follows:

| 2024 |     | USD | 66 |
|:-----|:----|:----|---:|
|      |     | $   | 66 |

The Company elected to apply the practical
expedients permitted under the transition guidance in ASU 2016-02, and the Company also elected not to apply the recognition requirements
in ASU 2016-02 to short-term leases (less than 12 months) as of the adoption date. As such, there was no impact on the Company’s
financial statements as a result of adopting ASU 2016-02.

|